Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel/Granulocyte Therapy for Recurrent/Metastatic Breast Cancer
NCT06496724Recruiting
- Sponsor
- Jiangsu Longwei Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of albumin-bound paclitaxel/granulocyte drug in breast cancer, sponsored by Jiangsu Longwei Pharmaceutical. Primary endpoint: Safety of Albumin-bound Paclitaxel/Granulocyte at 13 months. Started Jun 2024; status: recruiting.
02
Drugs
albumin-bound paclitaxel/granulocyte drug
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06496724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496724.